Publicaciones en las que colabora con Carlos Solano Vercet (10)

2024

  1. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies

    Bone Marrow Transplantation, Vol. 59, Núm. 10, pp. 1369-1375

  2. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

2022

  1. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10

2021

  1. Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs

    PLoS ONE, Vol. 16, Núm. 8 August

  2. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

    Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223

2020

  1. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: Study protocol for the prospective multicentre OptimBioma study

    BMJ Open, Vol. 10, Núm. 7

2018

  1. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

    Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737

2017

  1. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055

2015

  1. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10